{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:48:25Z","timestamp":1791967705902,"version":"4.3.4"},"update-to":[{"DOI":"10.12688\/openresafrica.16071.1","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000}}],"reference-count":59,"publisher":"F1000 Research Ltd","license":[{"start":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T00:00:00Z","timestamp":1771718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"GC Africa Round 10 \u2013 2nd Drug Discovery Grant","award":["Ref.No.GCA\/DD2\/Round10\/022\/002"],"award-info":[{"award-number":["Ref.No.GCA\/DD2\/Round10\/022\/002"]}]}],"content-domain":{"domain":["openresearchafrica.org"],"crossmark-restriction":false},"short-container-title":["Open Res Africa"],"abstract":"<ns5:p>\n                    Background\n                    <ns5:italic>Mycobacterium tuberculosis<\/ns5:italic>\n                    (\n                    <ns5:italic>Mtb<\/ns5:italic>\n                    ), the causative agent of tuberculosis (TB), is the leading cause of death due to a single infectious pathogen globally. The increasing prevalence of drug-resistant\n                    <ns5:italic>Mtb<\/ns5:italic>\n                    strains underscores the pressing need for the development of new antimycobacterial drugs with novel mechanisms of action. Targeting pathogen drug efflux, a key antimycobacterial drug resistance mechanism, is an attractive, viable strategy for the development of new TB therapeutics. Methods In this study, we utilised\n                    <ns5:italic>Mycobacterium smegmatis<\/ns5:italic>\n                    (\n                    <ns5:italic>Msm<\/ns5:italic>\n                    ), a non-pathogenic\n                    <ns5:italic>Mtb<\/ns5:italic>\n                    surrogate, to delineate the ability of natural-product based compounds to augment the efficacy of bedaquiline (BDQ), clofazimine (CFZ) and doxycycline (DOX), probably via efflux inhibition (EI). Literature reporting the plant sources of the known efflux inhibitors (EIs) reserpine (RES), berberine (BER) and piperine (PIP) was scoped and additional compounds, (+)-lyoniresinol-3-Alpha-O-Beta-D-glucopyranoside (LYO-3) and lyoniresinol (LYO), isolated from the same plant species were chosen for testing.\n                    <ns5:italic>In vitro<\/ns5:italic>\n                    screening of the selected compounds was performed using the two-dimensional (2-D) checkerboard assay in which each likely efflux disruptor was tested in combination with BDQ, CFZ and DOX against\n                    <ns5:italic>Msm<\/ns5:italic>\n                    and the effect of the combinations ascertained. Thereafter, compounds that exhibited probable EI activity were docked onto potential targets namely MSMEG_5187, a\n                    <ns5:italic>Msm<\/ns5:italic>\n                    homologue of\n                    <ns5:italic>Mtb<\/ns5:italic>\n                    Rv1258c efflux pump (EP) and MmpL5. Results Molecular docking revealed that the EIs avidly bound to the EPs with docking scores of &lt;-7 kcal\/mol while the checkerboard combination assays demonstrated strong synergistic interactions for BDQ plus BER, LYO-3 and LYO. Conclusion These results point to a probable disruption of the\n                    <ns5:italic>Msm<\/ns5:italic>\n                    efflux system by\n                    <ns5:italic>Berberis species<\/ns5:italic>\n                    derivatives.\n                  <\/ns5:p>","DOI":"10.12688\/openresafrica.16071.2","type":"journal-article","created":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T14:29:07Z","timestamp":1771770547000},"page":"23","update-policy":"https:\/\/doi.org\/10.12688\/openresafrica.crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Potentiation of the antimycobacterial activity of bedaquiline, clofazimine, and doxycycline against Mycobacterium smegmatis by several natural product-based compounds is putatively via efflux inhibition"],"prefix":"10.12688","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8566-1008","authenticated-orcid":false,"given":"Robi","family":"Chacha","sequence":"first","affiliation":[{"name":"Centre for Respiratory Diseases Research Nairobi Nairobi County Kenya Medical Research Institute"},{"name":"Department of Biochemistry, Microbiology and Biotechnology Nairobi Nairobi County Kenyatta University School of Pure and Applied Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-4399","authenticated-orcid":false,"given":"Caroline","family":"Maina","sequence":"additional","affiliation":[{"name":"Centre for Traditional Medicine and Drug Research Nairobi Nairobi County Kenya Medical Research Institute"},{"name":"Department of Chemistry Rondebosch Western Cape University of Cape Town Department of Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Murungi","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry Kisii Kisii County Kisii University College School of Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Guantai","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Clinical Pharmacy and Pharmacy Practice, Faculty of Health Sciences Nairobi Nairobi County University of Nairobi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew P.","family":"Ngugi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Microbiology and Biotechnology Nairobi Nairobi County Kenyatta University School of Pure and Applied Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-8868","authenticated-orcid":false,"given":"Ephantus","family":"Ndirangu","sequence":"additional","affiliation":[{"name":"Department of Chemistry Nairobi Nairobi County Kenyatta University Department of Chemistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Mugo","sequence":"additional","affiliation":[{"name":"Centre for Traditional Medicine and Drug Research Nairobi Nairobi County Kenya Medical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sospeter Ngoci","family":"Njeru","sequence":"additional","affiliation":[{"name":"Centre for Community Driven Research Kirinyaga, Kirinyaga County Kenya Medical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1927-8681","authenticated-orcid":false,"given":"Elizabeth","family":"Kigondu","sequence":"additional","affiliation":[{"name":"Centre for Traditional Medicine and Drug Research Nairobi Nairobi County Kenya Medical Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2560","published-online":{"date-parts":[[2026,2,22]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"13398","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management.","volume":"13","author":"P Agu","year":"2023","journal-title":"Sci Rep."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.701568","article-title":"Evaluation of the IKK\u03b2 binding of indicaxanthin by induced-fit docking, binding pose metadynamics, and molecular dynamics.","volume":"12","author":"M Allegra","year":"2021","journal-title":"Front Pharmacol."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets.","volume":"24","author":"S Alsayed","year":"2023","journal-title":"Int J Mol Sci."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e102135","DOI":"10.1371\/journal.pone.0102135","article-title":"Acquired resistance of Mycobacterium tuberculosis to bedaquiline.","volume":"9","author":"K Andries","year":"2014","journal-title":"PLoS One."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2326-2331","DOI":"10.1016\/j.xphs.2023.07.006","article-title":"Solubility-permeability interplay in facilitating the prediction of drug disposition routes, extent of absorption, food effects, brain penetration and drug induced liver injury potential.","volume":"112","author":"L Benet","year":"2023","journal-title":"J Pharm Sci."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1002\/cpph.67","article-title":"Natural products as a foundation for drug discovery.","volume":"86","author":"J Beutler","year":"2019","journal-title":"Curr Protoc Pharmacol."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3747-3764","DOI":"10.1007\/s12010-023-04731-3","article-title":"Screening of phytocompounds for identification of prospective histone deacetylase 1 (HDAC1) inhibitor: an in silico molecular docking, molecular dynamics simulation, and MM-GBSA approach.","volume":"196","author":"K Bharadwaj","year":"2024a","journal-title":"Appl Biochem Biotechnol."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"3747-3764","DOI":"10.1007\/s12010-023-04731-3","article-title":"Screening of phytocompounds for identification of prospective histone deacetylase 1 (HDAC1) inhibitor: an in silico molecular docking, molecular dynamics simulation, and MM-GBSA approach.","volume":"196","author":"K Bharadwaj","year":"2024b","journal-title":"Appl Biochem Biotechnol."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"121-134","DOI":"10.1111\/mmi.12448","article-title":"A complex regulatory network controlling intrinsic multidrug resistance in Mycobacterium smegmatis.","volume":"91","author":"J Bowman","year":"2014","journal-title":"Mol Microbiol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"20332","DOI":"10.1038\/s41598-023-47695-4","article-title":"Insight into the on\/off switch that regulates expression of the MSMEG-3762\/63 efflux pump in Mycobacterium smegmatis.","volume":"13","author":"N Campolattano","year":"2023","journal-title":"Sci Rep."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.5281\/zenodo.17163521","article-title":"Potentiation of the antimycobacterial activity of bedaquiline, clofazimine, and doxycycline against Mycobacterium smegmatis by several natural product-based compounds is putatively via efflux inhibition. [Data set].","author":"R Chacha","year":"2025","journal-title":"Open Research Africa. Zenodo."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e0207605","DOI":"10.1371\/journal.pone.0207605","article-title":"Molecular modelling and simulation studies of the Mycobacterium tuberculosis multidrug efflux pump protein Rv1258c.","volume":"13","author":"R Cloete","year":"2018","journal-title":"PLoS One."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e972-e982","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.","volume":"4","author":"B Derendinger","year":"2023","journal-title":"Lancet Microbe."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"116278","DOI":"10.1016\/j.ecoenv.2024","article-title":"Integrated network toxicology, molecular docking, and in vivo experiments to elucidate molecular mechanism of aflatoxin B1 hepatotoxicity.","volume":"275","author":"B Ge","year":"2024","journal-title":"Ecotoxicol Environ Saf."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"449-461","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities.","volume":"10","author":"S Genheden","year":"2015","journal-title":"Expert Opin Drug Discov."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2021.104737","article-title":"PNA-mediated efflux inhibition as a therapeutic strategy towards overcoming drug resistance in Mycobacterium smegmatis.","volume":"151","author":"S Ghosh","year":"2021","journal-title":"Microb Pathog."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"139-140","DOI":"10.1002\/(sici)1099-1573(200003)14:2<139::aid-ptr608>3.0.co;2-8","article-title":"The effect of reserpine, a modulator of multidrug efflux pumps, on the in vitro activity of tetracycline against clinical isolates of Methicillin Resistant Staphylococcus aureus (MRSA) possessing the tet(K) determinant.","volume":"14","author":"S Gibbons","year":"2000","journal-title":"Phytother Res."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2189-2198","DOI":"10.1021\/acs.jcim.0c00057","article-title":"Improving protein-ligand docking results with high-throughput molecular dynamics simulations.","volume":"60","author":"H Guterres","year":"2020","journal-title":"J Chem Inf Model."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"2979-2981","DOI":"10.1128\/AAC.00037-14","article-title":"Cross-resistance between clofazimine and bedaquiline through upregulation of mmpl5 in Mycobacterium tuberculosis.","volume":"58","author":"R Hartkoorn","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"271-283","DOI":"10.1515\/BMC.2010.022","article-title":"A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins.","volume":"1","author":"S Hollingsworth","year":"2010","journal-title":"Biomol Concepts."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"789-794","DOI":"10.1016\/j.jfma.2012.03.009","article-title":"Inhibition of the Mycobacterium tuberculosis reserpine-sensitive efflux pump augments intracellular concentrations of ciprofloxacin and enhances susceptibility of some clinical isolates.","volume":"112","author":"T Huang","year":"2013","journal-title":"J Formos Med Assoc."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1255-1264","DOI":"10.1016\/j.jiph.2020.06.023","article-title":"Features of the biochemistry of Mycobacterium smegmatis, as a possible model for Mycobacterium tuberculosis.","volume":"13","author":"T Joseph Antony Sundarsingh","year":"2020","journal-title":"J Infect Public Health."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"223-229","DOI":"10.1099\/jmm.0.025734-0","article-title":"The plant alkaloid piperine as a potential inhibitor of ethidium bromide efflux in Mycobacterium smegmatis.","volume":"60","author":"G Jin","year":"2011","journal-title":"J Med Microbiol."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/5583342","article-title":"Antimycobacterial activity, synergism, and mechanism of action evaluation of novel polycyclic amines against Mycobacterium tuberculosis.","volume":"2021","author":"E Kapp","year":"2021","journal-title":"Adv Pharmacol Pharm Sci."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"5872-5882","DOI":"10.1021\/acs.jctc.9b00742","article-title":"Solvation free energy as a measure of hydrophobicity: application to serine protease binding interfaces.","volume":"15","author":"J Kraml","year":"2019","journal-title":"J Chem Theory Comput."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"57-68","DOI":"10.1016\/j.tim.2021.05.001","article-title":"Efflux pumps in Mycobacterium tuberculosis and their inhibition to tackle antimicrobial resistance.","volume":"30","author":"M Laws","year":"2022","journal-title":"Trends Microbiol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e0332422","DOI":"10.1128\/spectrum.03324-22","article-title":"Role of Berberine as a potential efflux pump inhibitor against MdfA from Escherichia coli: In Vitro and In Silico studies.","volume":"11","author":"Y Li","year":"2023a","journal-title":"Microbiol Spectr."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e0332422","DOI":"10.1128\/spectrum.03324-22","article-title":"Role of Berberine as a potential efflux pump inhibitor against MdfA from Escherichia coli: In Vitro and In Silico studies.","volume":"11","author":"Y Li","year":"2023b","journal-title":"Microbiol Spectr."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2415-2423","DOI":"10.1128\/AAC.48.7.2415-2423.2004","article-title":"Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis.","volume":"48","author":"X Li","year":"2004","journal-title":"Antimicrob Agents Chemother."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"216","DOI":"10.3389\/fmicb.2019.00216","article-title":"Mutations in efflux pump Rv1258c (Tap) cause resistance to pyrazinamide, isoniazid, and streptomycin in M. tuberculosis.","volume":"10","author":"J Liu","year":"2019","journal-title":"Front Microbiol."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"337-341","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: The rule-of-five revolution.","volume":"1","author":"C Lipinski","year":"2004","journal-title":"Drug Discov Today Technol."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3390\/molecules25071622","article-title":"Structure-based Site of Metabolism (SOM) prediction of ligand for CYP3A4 enzyme: comparison of glide XP and Induced Fit Docking (IFD).","volume":"25","author":"D Lokwani","year":"2020","journal-title":"Molecules."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"331-348","DOI":"10.1515\/hsz-2019-0326","article-title":"Transport mechanism of Mycobacterium tuberculosis MmpL\/S family proteins and implications in pharmaceutical targeting.","volume":"401","author":"S Ma","year":"2020","journal-title":"Biol Chem."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1529-1541","DOI":"10.1007\/s11224-022-01921-3","article-title":"Identification of novel TMPRSS2 inhibitors against SARS-CoV-2 infection: a structure-based virtual screening and molecular dynamics study.","volume":"33","author":"S Manandhar","year":"2022","journal-title":"Struct Chem."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"859-867","DOI":"10.1016\/j.str.2011.03.010","article-title":"Relative solvent accessible surface area predicts protein conformational changes upon binding.","volume":"19","author":"J Marsh","year":"2011","journal-title":"Structure."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"128-132","DOI":"10.1038\/s41429-019-0245-1","article-title":"Effect of efflux pump inhibitors on the susceptibility of Mycobacterium avium complex to clarithrsomycin.","volume":"73","author":"M Menichini","year":"2020","journal-title":"J Antibiot (Tokyo)."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"8-15","DOI":"10.4103\/0973-7847.125517","article-title":"Phytochemistry and pharmacology of Berberis species.","volume":"8","author":"N Mokhber-Dezfuli","year":"2014","journal-title":"Pharmacogn Rev."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3389\/fmicb.2016.01223","article-title":"Berberine is a novel type efflux inhibitor which attenuates the MexXY-mediated aminoglycoside resistance in Pseudomonas aeruginosa.","volume":"7","author":"Y Morita","year":"2016","journal-title":"Front Microbiol."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"55-63","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.","volume":"65","author":"T Mosmann","year":"1983","journal-title":"J Immunol Methods."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e06605","article-title":"Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors.","volume":"7","author":"N Moussa","year":"2021","journal-title":"Heliyon."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12906-024-04348-x","article-title":"Synergistic effect of potential alpha-amylase inhibitors from Egyptian propolis with acarbose using in silico and in vitro combination analysis.","volume":"24","author":"A Nada","year":"2024","journal-title":"BMC Complement Med Ther."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00894-022-05060-8","article-title":"Identification of behenic acid as medicinal food for the diabetes mellitus: structure-based computational approach and molecular dynamics simulation studies.","volume":"28","author":"V Nath","year":"2022","journal-title":"J Mol Model."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"479-481","DOI":"10.24425\/pjvs.2022.142034","article-title":"Effect of alkaloid Berberine on the susceptibility of Nontuberculous Mycobacteria to antibiotics.","volume":"25","author":"K Puk","year":"2022","journal-title":"Pol J Vet Sci."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"272-288","DOI":"10.2174\/1389557523666230406092128","article-title":"Plant-based natural products as inhibitors for efflux pumps to reverse multidrug resistance in Staphylococcus aureus: a mini review.","volume":"24","author":"S Ramalingam","year":"2024","journal-title":"Mini Rev Med Chem."},{"key":"ref46","doi-asserted-by":"publisher","first-page":"3861-3869","DOI":"10.1128\/AAC.00474-11","article-title":"Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen.","volume":"55","author":"S Ram\u00f3n-Garc\u00eda","year":"2011","journal-title":"Antimicrob Agents Chemother."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"409-412","DOI":"10.1038\/s41586-020-2072-8","article-title":"A mycobacterial ABC transporter mediates the uptake of hydrophilic compounds.","volume":"580","author":"S Rempel","year":"2020","journal-title":"Nature."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"4191","DOI":"10.3390\/ijms21124191","article-title":"Efflux pump inhibitors against nontuberculous mycobacteria.","volume":"21","author":"L Rindi","year":"2020","journal-title":"Int J Mol Sci."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"2023-2037","DOI":"10.1148\/rg.2019190109","article-title":"Extrapulmonary tuberculosis: pathophysiology and imaging findings.","volume":"39","author":"S Rodriguez-Takeuchi","year":"2019","journal-title":"Radiographics."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"321-324","DOI":"10.1016\/j.ymeth.2007.01.006","article-title":"Microtitre plate-based antibacterial assay incorporating resazurin as an indicator of cell growth, and its application in the in vitro antibacterial screening of phytochemicals.","volume":"42","author":"S Sarker","year":"2007","journal-title":"Methods."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"15-33","DOI":"10.1164\/rccm.202410-2096ST","article-title":"Updates on the treatment of drug-susceptible and drug-resistant tuberculosis: an official ATS\/CDC\/ERS\/IDSA clinical practice guideline.","volume":"211","author":"J Saukkonen","year":"2025","journal-title":"Am J Respir Crit Care Med."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"277-290","DOI":"10.1016\/j.jpha.2019.11.002","article-title":"Plant-derived secondary metabolites as the main source of efflux pump inhibitors and methods for identification.","volume":"10","author":"A Seukep","year":"2020","journal-title":"J Pharm Anal."},{"key":"ref54","doi-asserted-by":"publisher","first-page":"596-605","DOI":"10.1134\/S0026898419040128","article-title":"Reserpine is the new addition into the repertoire of AcrB efflux pump inhibitors.","volume":"53","author":"A Shaheen","year":"2019a","journal-title":"Mol Biol (Mosk)."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"596-605","DOI":"10.1134\/S0026898419040128","article-title":"Reserpine is the new addition into the repertoire of AcrB efflux pump inhibitors.","volume":"53","author":"A Shaheen","year":"2019b","journal-title":"Mol Biol (Mosk)."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"106486","DOI":"10.1016\/j.micpath.2023","article-title":"In-vitro and in-silico anti-HSV-1 activity of a marine steroid from the jellyfish Cassiopea andromeda venom.","volume":"186","author":"S Shamsian","year":"2024","journal-title":"Microb Pathog."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1694-1701","DOI":"10.1093\/jac\/dkq186","article-title":"Piperine as an inhibitor of Rv1258c, a putative multidrug efflux pump of Mycobacterium tuberculosis.","volume":"65","author":"S Sharma","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"1547-1567","DOI":"10.1111\/jam.14478","article-title":"Recent updates on drug resistance in Mycobacterium tuberculosis.","volume":"128","author":"R Singh","year":"2020","journal-title":"J Appl Microbiol."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"D368-D375","DOI":"10.1093\/nar\/gkad1011","article-title":"AlphaFold Protein Structure Database in 2024: providing structure coverage for over 214 million protein sequences.","volume":"52","author":"M Varadi","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"1199-1212","DOI":"10.1021\/ci300064d","article-title":"Develop and test a solvent accessible surface area-based model in conformational entropy calculations.","volume":"52","author":"J Wang","year":"2012","journal-title":"J Chem Inf Model."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"W296-W303","DOI":"10.1093\/nar\/gky427","article-title":"SWISS-MODEL: Homology modelling of protein structures and complexes.","volume":"46","author":"A Waterhouse","year":"2018","journal-title":"Nucleic Acids Res."}],"container-title":["Open Research Africa"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2\/pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2\/iparadigms","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T08:04:33Z","timestamp":1791965073000},"score":1,"resource":{"primary":{"URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,22]]},"references-count":59,"URL":"https:\/\/doi.org\/10.12688\/openresafrica.16071.2","relation":{"has-version":[{"id-type":"doi","id":"10.12688\/openresafrica.16071.1","asserted-by":"subject"}],"has-review":[{"id-type":"doi","id":"10.21956\/openresafrica.17627.r33826","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/openresafrica.17627.r33834","asserted-by":"subject"},{"id-type":"doi","id":"10.21956\/openresafrica.17627.r33826","asserted-by":"object"},{"id-type":"doi","id":"10.21956\/openresafrica.17627.r33834","asserted-by":"object"}]},"ISSN":["2752-6925"],"issn-type":[{"value":"2752-6925","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,22]]},"assertion":[{"value":"Indexed","URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2#article-reports","order":0,"name":"referee-status","label":"Referee status","group":{"name":"current-referee-status","label":"Current Referee Status"}},{"value":"10.21956\/openresafrica.17627.r33826, Carine Sao Emani, Leibniz Lung Center, Borstal, 25 Feb 2026, version 2, indexed","URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2#referee-response-33826","order":0,"name":"referee-response-33826","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/openresafrica.17246.r33527, Mustapha Belaidi, University of Sciences and Technologies of Oran, Oran, 12 Jan 2026, version 1, 2 approved with reservations","URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v1#referee-response-33527","order":1,"name":"referee-response-33527","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"<b>ROBI CHACHA<\/b>; \n<i>Posted: 07 Feb 2026<\/i>; \n<b>Manuscript response to reviewers<\/b>  R-1: Conduct Functional Efflux Assays: Perform ethidium bromide (or fluorescent antibiotic) accumulation\/efflux assays with and without the lead compounds.  R-2: Can you evaluate the effect of LYO and LYO-3 on efflux activities (with and without the tested antibiotics) using the method based on Ethidium Bromide or Nile Red, or 1,2\u2032-Dinaphthylamine or Doxorubicin or the ColorFlux kit? \n<b>Response:<\/b> We acknowledge the importance of direct functional efflux assays (e.g., ethidium bromide, Nile Red, 1,2\u2032-dinaphthylamine, doxorubicin, or ColorFlux-based methods) for mechanistic confirmation of efflux inhibition. However, setting up these assays is \n<b>not feasible within the scope of the present study<\/b> due to constrained funding and the fixed timelines of the Master\u2019s training period under which the work was conducted. This limitation has now been \n<b>explicitly stated in the revised manuscript<\/b>. There are\n<b> efforts to secure additional funding<\/b>&nbsp;that will enable the inclusion of these functional efflux assays in subsequent studies to further substantiate the findings. &nbsp;  Validate in&nbsp;\n<i>M. tuberculosis<\/i>: Test synergistic combinations in relevant \n<i>Mtb<\/i> strains, including MDR\/XDR isolates.  &nbsp; \n<b>Response:<\/b> We recognize the importance of validating synergistic combinations in \n<i>Mycobacterium tuberculosis<\/i>, including MDR\/XDR isolates. However, it is challenging to do these experiments within the current study due to funding limitations, biosafety requirements, and the fixed timelines of the Master\u2019s training framework. This has now been \n<b>clearly stated as a study limitation<\/b> in the revised manuscript. \n<b>Additional funding is currently being sought<\/b> to support validation in \n<i>M. tuberculosis<\/i>, including MDR\/XDR clinical isolates, in future studies. &nbsp;  Explore Genetic Validation: Use knockdown or knockout strains of the target efflux pumps to confirm the mechanism.  &nbsp; \n<b>Response<\/b>: Genetic confirmation through targeted knockdown or knockout of candidate efflux pump genes would provide definitive mechanistic evidence. Such approaches, however, involve considerable technical complexity, extended development timelines, additional funding and specialized infrastructure that we currently are unable to explore within this study. This consideration has now been \n<b>integrated into the limitations section<\/b> of the manuscript. Future studies, contingent on \n<b>additional funding currently being pursued<\/b>\n<b>,<\/b> will incorporate genetic validation to further substantiate the proposed mechanism. &nbsp;  Initiate Medicinal Chemistry: Optimize the most promising leads (e.g., LYO-3) based on computational insights to improve potency and reduce toxicity.  &nbsp; \n<b>Response<\/b>: We agree that medicinal chemistry optimisation of the most promising lead compounds, particularly LYO-3, guided by computational insights, would be a logical and impactful progression of this work. However, such iterative structure-activity optimisation and toxicity refinement require dedicated chemistry resources, extended timelines, and substantial financial investment that are not currently available for this study. This aspect has now been \n<b>identified as a future research direction<\/b> in the revised manuscript. \n<b>Funding and potential collaborators are currently being sought<\/b> to support medicinal chemistry-driven optimisation of lead compounds in subsequent studies. &nbsp;  In the introduction, an information is missing in this line, after and \u2018\u2019 linezolid, and (Saukkonen et al., 2025; Singh et al., 2020).\u2019\u2019_  \n<b>Response:<\/b> The missing information has been added.  Can you perform an RT-PCR quantification of the expression of the genes encoding \n<i>MSMEG_5187<\/i> and MmpL5 when \n<i>Msm<\/i> is treated with either LYO or LYO-3?  \n<b>Response:<\/b> Quantitative RT-PCR analysis of \n<i>MSMEG_5187<\/i> and \n<i>mmpL5<\/i> expression following treatment with LYO or LYO-3 would provide complementary molecular evidence supporting efflux modulation. While technically feasible, these experiments cannot be completed within the current study due to resource limitations and competing timeline constraints associated with the training framework. This has now been \n<b>explicitly acknowledged as a study limitation<\/b>\n<b>. <\/b>\n<b>Ongoing efforts to secure additional funding<\/b> will enable targeted transcriptional analyses to directly assess efflux pump regulation in future work.  Can you also provide the MIC values in Molar concentrations?  \n<b>Response<\/b>: all the values have been converted to &micro;M  Have you searched through the literature to find out if an \u2206\n<i>MSMEG_5187<\/i>&nbsp;\n<i>Msm<\/i> mutant has been generated and characterized before? If yes, what was the phenotype of this mutant? Was it sensitive to antibiotics?  \n<b>Response:<\/b> A thorough literature search was conducted and did not find any published studies reporting the generation or phenotypic characterization of an \u2206\n<i>MSMEG_5187<\/i> mutant in \n<i>Mycobacterium smegmatis<\/i>. While \n<i>MSMEG_5187<\/i> is annotated as a putative TetV-like efflux pump and has been implicated indirectly through transcriptomic studies of regulatory mutants, there are no reports describing its deletion or associated antibiotic susceptibility phenotype. Therefore, the antibiotic sensitivity of an \u2206\n<i>MSMEG_5187<\/i> mutant has not been previously documented.  Can you improve the resolution of Figure 3?  \n<b>Response:<\/b> This has been improved.","URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2#referee-comment-3319","order":2,"name":"referee-comment-3319","label":"Referee Comment","group":{"name":"article-reports","label":"Article Reports"}},{"value":"10.21956\/openresafrica.17627.r33834, Milagros Zavaleta, Research and developmentBTS Consultores S.A.C., Lima, 13 Apr 2026, version 2, indexed","URL":"https:\/\/openresearchafrica.org\/articles\/8-23\/v2#referee-response-33834","order":3,"name":"referee-response-33834","label":"Referee Report","group":{"name":"article-reports","label":"Article Reports"}},{"value":"This work was supported by Grand Challenges (GC) Africa Round 10 \u2013 2nd Drug Discovery Grant [Ref. No. GCA\/DD2\/Round10\/022\/002] awarded to EK. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":4,"name":"grant-information","label":"Grant Information"},{"value":"This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.","order":0,"name":"copyright-info","label":"Copyright"}]}}